XBiotech (XBiotech) EPS (Basic) : $-0.82 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is XBiotech EPS (Basic)?

XBiotech's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.16. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.82.

XBiotech's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.82.

XBiotech's EPS without NRI for the three months ended in Dec. 2023 was $-0.20. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.88.

During the past 3 years, the average EPS without NRI Growth Rate was -23.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -10.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was -1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, XBiotech's highest 3-Year average EPS without NRI Growth Rate was 27.60% per year. The lowest was -73.30% per year. And the median was -12.00% per year.

XBiotech EPS (Basic) Historical Data

The historical data trend for XBiotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech EPS (Basic) Chart

XBiotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

17.17

-0.36

-0.58

-1.08

-0.81

XBiotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.10	-0.13	-0.29	-0.24	-0.16

XBiotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

XBiotech's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-24.557	-	0)	/	30.438
	=	-0.81

XBiotech's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-4.635	-	0)	/	30.443
	=	-0.15

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82

XBiotech (NAS:XBIT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

XBiotech EPS (Basic) Related Terms

Thank you for viewing the detailed overview of XBiotech's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

XBiotech (XBiotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

4XB:Germany 4XB:Germany

Address

5217 Winnebago Lane, Austin, TX, USA, 78744

Website

http://www.xbiotech.com

XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Executives

Angela Hu	officer: Principle Financial Officer	5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard	director, 10 percent owner	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a.	10 percent owner	MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie	director, 10 percent owner	735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy	officer: VP of R&D	8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han	officer: VP of Fin & HR, Secretary	8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut	10 percent owner	CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby	director	109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes	10 percent owner	RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam	director	56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin	director	77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman	officer: Sr.VP Corp. Strategy & Finance	8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson	officer: VP of Commercial Development	8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury	officer: VP of Business Development	8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough	officer: VP Clinical Operations	115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703